Substance / Medication

Dextran 70

Overview

Active Ingredient
dextran 70
RxNorm CUI
3274

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Comparison of the plasma volume-expanding effects of 6% dextran 70, 5% albumin, and 6% HES 130/0.4 after hemorrhage in the guinea pig.
Dubniks Maris, Persson Johan, Grände Per-Olof · J Trauma · 2009
PMID: 20009667Observational
Preparation and Anti-tumor Study of Dextran 70,000-Selenium Nanoparticles and Poloxamer 188-Selenium Nanoparticles.
Wang Zhenzhen, Ji Liyuan, Ren Yimeng et al. · AAPS PharmSciTech · 2021
PMID: 34931279Other
Intravenous dextran 70 infusion has protective effects on ischemia reperfusion injury of kidney: an experimental study.
Semercioz Atilla, Temiz Mustafa Z, Erbarut Ipek et al. · Minerva Urol Nefrol · 2018
PMID: 29161807Preclinical
Effect of Dextran 70 on the thermodynamic and structural properties of proteins.
Sharma Gurumayum Suraj, Mittal Shruti, Singh Laishram Rajendrakumar · Int J Biol Macromol · 2015
PMID: 25936502Preclinical
Phase II trial on the use of Dextran 70 or starch for supportive therapy in Kenyan children with severe malaria.
Akech Samuel O, Jemutai Julie, Timbwa Molline et al. · Crit Care Med · 2010
PMID: 20526196Trial
Comparing the effects of Dextran 70 and Hydroxyethyl starch in an intestinal storage solution.
Kokotilo Matthew S, Schlachter Kimberly, Carter Jodi et al. · Cryobiology · 2010
PMID: 20863823Preclinical
The effect of intravenous dextran 70 on enteric bacterial translocation after partial hepatectomy in rats.
Nafeh Ayman I, Sorour Ashraf E · J Egypt Soc Parasitol · 2007
PMID: 17926809Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Dextran 70 (substance)
SNOMED CT
12391001
UMLS CUI
C0011795
RxNorm CUI
3274

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.